IFM Investors Pty Ltd lifted its position in Eli Lilly and Company (NYSE:LLY) by 16.3% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 83,100 shares of the company’s stock after buying an additional 11,661 shares during the period. IFM Investors Pty Ltd’s holdings in Eli Lilly and were worth $14,031,000 at the end of the most recent reporting period.
Several other institutional investors have also recently made changes to their positions in the company. HT Partners LLC boosted its stake in Eli Lilly and by 1.4% during the fourth quarter. HT Partners LLC now owns 4,428 shares of the company’s stock valued at $748,000 after buying an additional 61 shares in the last quarter. KMG Fiduciary Partners LLC lifted its holdings in Eli Lilly and by 2.0% in the 3rd quarter. KMG Fiduciary Partners LLC now owns 3,392 shares of the company’s stock valued at $502,000 after acquiring an additional 67 shares during the last quarter. Veracity Capital LLC boosted its position in shares of Eli Lilly and by 3.2% during the 3rd quarter. Veracity Capital LLC now owns 2,358 shares of the company’s stock valued at $349,000 after purchasing an additional 73 shares in the last quarter. Prestige Wealth Management Group LLC boosted its position in shares of Eli Lilly and by 11.6% during the 3rd quarter. Prestige Wealth Management Group LLC now owns 722 shares of the company’s stock valued at $107,000 after purchasing an additional 75 shares in the last quarter. Finally, Platform Technology Partners grew its stake in shares of Eli Lilly and by 2.1% in the 3rd quarter. Platform Technology Partners now owns 3,715 shares of the company’s stock worth $550,000 after purchasing an additional 75 shares during the last quarter. Institutional investors and hedge funds own 69.85% of the company’s stock.
In related news, major shareholder Lilly Endowment Inc sold 220,000 shares of the firm’s stock in a transaction that occurred on Monday, January 11th. The shares were sold at an average price of $185.49, for a total transaction of $40,807,800.00. Following the transaction, the insider now owns 111,003,815 shares of the company’s stock, valued at $20,590,097,644.35. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 0.09% of the company’s stock.
Shares of LLY stock traded up $6.70 during trading on Wednesday, hitting $185.50. 7,266,433 shares of the company were exchanged, compared to its average volume of 5,180,701. The business’s 50-day simple moving average is $161.85 and its 200 day simple moving average is $153.50. Eli Lilly and Company has a twelve month low of $117.06 and a twelve month high of $189.30. The firm has a market capitalization of $177.45 billion, a price-to-earnings ratio of 30.31, a P/E/G ratio of 1.52 and a beta of 0.34. The company has a debt-to-equity ratio of 3.27, a quick ratio of 1.06 and a current ratio of 1.36.
Eli Lilly and (NYSE:LLY) last released its earnings results on Sunday, November 1st. The company reported $1.54 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.71 by ($0.17). Eli Lilly and had a return on equity of 166.45% and a net margin of 24.01%. The company had revenue of $5.74 billion during the quarter, compared to analysts’ expectations of $5.87 billion. During the same quarter in the previous year, the company earned $1.48 EPS. The firm’s quarterly revenue was up 4.8% compared to the same quarter last year. On average, equities analysts forecast that Eli Lilly and Company will post 7.21 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Wednesday, March 10th. Shareholders of record on Friday, February 12th will be given a $0.85 dividend. This is a positive change from Eli Lilly and’s previous quarterly dividend of $0.74. This represents a $3.40 annualized dividend and a yield of 1.83%. The ex-dividend date is Thursday, February 11th. Eli Lilly and’s dividend payout ratio is presently 49.01%.
Eli Lilly and Company Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. It offers endocrinology products for diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and paediatric growth conditions. The company also provides neuroscience products for treating depressive disorder, diabetic peripheral neuropathic pain, anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; migraine and episodic cluster headache; attention-deficit hyperactivity disorder; and schizophrenia.
Featured Article: What is basic economics?
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.